CNCR vs. SURI

Last updated Apr 3, 2026

Compare and contrast key facts about Loncar Cancer Immunotherapy ETF (CNCR) and Simplify Propel Opportunities ETF (SURI).

CNCR and SURI are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. CNCR is a passively managed fund by Exchange Traded Concepts that tracks the performance of the Loncar Cancer Immunotherapy Index. It was launched on Oct 13, 2015. SURI is an actively managed fund by Simplify. It was launched on Feb 7, 2023.

Performance

CNCR vs. SURI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Simplify Propel Opportunities ETF (SURI). The values are adjusted to include any dividend payments, if applicable.

CNCR vs. SURI - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
SURI Simplify Propel Opportunities ETF	2.75%

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

SURI

• 1D: 1.21%
• 1M: -2.83%
• YTD: -0.79%
• 6M: 7.48%
• 1Y: 22.70%
• 3Y*: 7.70%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. SURI - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is lower than SURI's 2.51% expense ratio.

SURI

Simplify Propel Opportunities ETF

CNCR

Loncar Cancer Immunotherapy ETF

Return for Risk

CNCR vs. SURI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SURI

SURI Risk / Return Rank: 44
SURI Sharpe Ratio Rank: 44
SURI Sortino Ratio Rank: 45
SURI Omega Ratio Rank: 39
SURI Calmar Ratio Rank: 49
SURI Martin Ratio Rank: 44

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. SURI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Simplify Propel Opportunities ETF (SURI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	SURI	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	0.88	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.08	—

Dividends

CNCR vs. SURI - Dividend Comparison

CNCR has not paid dividends to shareholders, while SURI's dividend yield for the trailing twelve months is around 17.16%.

	TTM	2025	2024	2023
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%
SURI Simplify Propel Opportunities ETF	17.16%	16.31%	21.41%	14.71%

Drawdowns

CNCR vs. SURI - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum SURI drawdown of -47.76%. Use the drawdown chart below to compare losses from any high point for CNCR and SURI.

Drawdown Indicators

	CNCR	SURI	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-47.76%	+47.76%
Max Drawdown (1Y) Largest decline over 1 year	—	-12.35%	—
Current Drawdown Current decline from peak	0.00%	-22.82%	+22.82%
Average Drawdown Average peak-to-trough decline	0.00%	-17.43%	+17.43%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	5.09%	—

Volatility

Volatility by Period

	CNCR	SURI	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	6.90%	—
Volatility (6M) Calculated over the trailing 6-month period	—	16.74%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	26.13%	-26.13%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	28.60%	-28.60%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	28.60%	-28.60%